Nutritional interventions for the adjunctive treatment of schizophrenia: A brief review

Nutrition Journal

Volumn 13, Issue 1, 2014, Pages

  Arroll, Megan Anne ^a   Wilder, Lorraine ^b   Neil, James ^b  

^a Food for the Brain Foundation   (United Kingdom)

^b Centre for Nutrition Education and Lifestyle Management   (United Kingdom)

Author keywords

Adjunct treatment; Mental health; Nutrition; Personalised medicine; Schizophrenia

Indexed keywords

ACETYLCYSTEINE; CARBON; CASEIN; FOLIC ACID; MELATONIN; POLYUNSATURATED FATTY ACID; THEANINE; THIOCTIC ACID; VITAMIN B GROUP; VITAMIN D; ALPHA TOCOPHEROL; ASCORBIC ACID; GLUTAMIC ACID DERIVATIVE; NEUROLEPTIC AGENT; UNSATURATED FATTY ACID; VITAMIN B COMPLEX;

CARBON METABOLISM; GLUTEN FREE DIET; HUMAN; META ANALYSIS (TOPIC); NUTRITIONAL SUPPORT; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SCHIZOPHRENIA; SYSTEMATIC REVIEW (TOPIC); VITAMIN SUPPLEMENTATION; DIET SUPPLEMENTATION; DIET THERAPY; DRUG EFFECTS; FACTUAL DATABASE;

ACETYLCYSTEINE; ANTIPSYCHOTIC AGENTS; ASCORBIC ACID; DATABASES, FACTUAL; DIET, GLUTEN-FREE; DIETARY SUPPLEMENTS; FATTY ACIDS, UNSATURATED; FOLIC ACID; GLUTAMATES; HUMANS; MELATONIN; OXIDATIVE STRESS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; THIOCTIC ACID; VITAMIN B COMPLEX; VITAMIN D; VITAMIN E;

EID: 84908030379     PISSN: None     EISSN: 14752891     Source Type: Journal    
DOI: 10.1186/1475-2891-13-91     Document Type: Review

References (112)

1. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. McGrath J, Saha S, Welham J, El Saadi O, MacCauley C, Chant D, BMC Med 2004 2 1 13
2. American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders 4th edition Washington DC: Amer Psychiatric Pub Inc 1994
3. The influence of age and sex on the onset and early course of schizophrenia. Maurer K, Riecher-R A, Br J Psychiatry 1993 162 1 80 86
4. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Breier A, Schreiber JL, Dyer J, Pickar D, Arch Gen Psychiatry 1991 48 3 239
5. The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. Petronis A, Biol Psychiatry 2004 55 10 965 970
6. Schizophrenia Commission, The Abandoned Illness (Schizophrenia Commission Report) London: Rethink Mental Illness 2012
7. Psychiatric comorbidity among adults with schizophrenia: A latent class analysis. Tsai J, Rosenheck RA, Psychiatry Res 2013 210 1 16 20
8. Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Schoepf D, Uppal H, Potluri R, Heun R, Eur Arch Psychiatry Clin Neurosci 2014 264 1 3 28
9. Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Crump C, Winkleby MA, Sundquist K, Sundquist J, Am J Psychiatr 2013 170 3 324 333
10. Schizophrenia and increased risks of cardiovascular disease. Hennekens CH, Hennekens AR, Hollar D, Casey DE, Am Heart J 2005 150 6 1115 1121
11. Life expectancy and cardiovascular mortality in persons with schizophrenia. Laursen TM, Munk-Olsen T, Vestergaard M, Curr Opin Psychiatry 2012 25 2 83 88
12. Dopamine hypothesis of schizophrenia: making sense of it all. Toda M, Abi-Dargham A, Curr Psychiatry Rep 2007 9 4 329 336
13. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. Snyder SH, Am J Psychiatry 1976 133 2 197 202
14. Dopamine in schizophrenia: a review and reconceptualization. Davis KL, Kahn RS, Ko G, Davidson M, Am J Psychiatry 1991 148 11 1474 1486
15. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Howes OD, Kapur S, Schizophr Bull 2009 35 3 549 562
16. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA, Schizophr Bull 2007 33 5 1120 1130
17. Bentall RP, Doctoring the Mind: Why Psychiatric Treatments Fail London: Penguin 2009
18. Ritsner MS, Is a Neuroprotective Therapy Suitable for Schizophrenia Patients? Brain Protection in Schizophrenia, Mood and Cognitive Disorders Netherlands: Springer 2010 343 395
19. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Kohen R, Nyska A, Toxicol Pathol 2002 30 6 620 650 Epub 2003/01/07
20. Oxidative stress involvement in schizophrenia pathophysiology: a review. Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L, L'Encéphale 2005 32 2 Pt 1 244 252
21. A meta-analysis of oxidative stress markers in schizophrenia. Zhang M, Zhao Z, He L, Wan C, Sci China Life Sci 2010 53 1 112 124
22. Oxidative stress in schizophrenia: an integrated approach. Bitanihirwe BK, Woo T-UW, Neurosci Biobehav Rev 2011 35 3 878 893
23. Oxidative stress in schizophrenia-focusing on the main markers. Ciobica A, Padurariu M, Dobrin I, Stefanescu C, Dobrin R, Psychiatr Danub 2011 23 3 237 245
24. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Wood SJ, Yücel M, Pantelis C, Berk M, Ann Acad Med Singapore 2009 38 5 396 401
25. Altered glutathione redox state in schizophrenia. Yao JK, Leonard S, Reddy R, Dis Markers 2006 22 1 83 93
26. Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Gawryluk JW, Wang J-F, Andreazza AC, Shao L, Young LT, Int J Neuropsychopharmacol 2011 14 01 123 130
27. The systemic availability of oral glutathione. Witschi A, Reddy S, Stofer B, Lauterburg B, Eur J Clin Pharmacol 1992 43 6 667 669
28. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, Bovet P, Bush AI, Conus P, Copolov D, Fornari E, Meuli R, Solida A, Vianin P, Cuénod M, Buclin T, Do KQ, Neuropsychopharmacology 2008 33 9 2187 2199
29. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Farokhnia M, Azarkolah A, Adinehfar F, Khodaie-Ardakani M-R, Hosseini S-M-R, Yekehtaz H, Tabrizi M, Rezaei F, Salehi B, Sadeghi S-M-H, Moghadam M, Gharibi F, Mirshafiee O: Akhondzadeh S, Clin Neuropharmacol 2013 36 6 185 192
30. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Busha AI, Biol Psychiatry 2008 64 5 361 368
31. Thioctic acid in therapy of schizophrenia. Giamattei L, Osp Psichiatr 1957 25 2 221
32. A preliminary investigation of α-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia. Kim E, Park D-W, Choi S-H, Kim J-J, Cho H-S, J Clin Psychopharmacol 2008 28 2 138 146
33. Role of adenosine monophosphate-activated protein kinase in the control of energy homeostasis. Foufelle F, Ferré P, Curr Opin Clin Nutr Metab Care 2005 8 4 355 360
34. Is it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia? Seybolt SE, Med Hypotheses 2010 75 6 572 575
35. Free radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Reiter RJ, Acuna-Castroviejo D, Tan DX, Burkhardt S, Ann N Y Acad Sci 2001 939 200 215 Epub 2001/07/21
36. Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics. Monteleone P, Maj M, Fusco M, Kemali D, Reiter RJ, Schizophr Res 1992 7 1 77 84
37. Decreased nocturnal secretion of melatonin in drug-free schizophrenics: no change after subchronic treatment with antipsychotics. Monteleone P, Natale M, La Rocca A, Maj M, Neuropsychobiology 1997 36 4 159 163
38. Nocturnal plasma melatonin levels in schizophrenic patients. Fanget F, Claustrat B, Dalery J, Brun J, Terra J-L, Marie-Cardine M, Guyotat J, Biol Psychiatry 1989 25 4 499 501
39. Sleep disturbance in schizophrenia. Monti JM, Monti D, Int Rev Psychiatry 2005 17 4 247 253
40. Melatonin improves sleep quality of patients with chronic schizophrenia. Shamir E, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, Zisapel N, J Clin Psychiatry 2000 61 5 373 377
41. Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. Suresh KP, Andrade C, Bhakta SG, Singh NM, J Clin Psychiatry 2007 68 2 237 241
42. Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects. Anderson G, Maes M, Metab Brain Dis 2012 27 2 113 119
43. Putative neuroprotective agents in neuropsychiatric disorders. Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M, Prog Neuro-Psychopharmacol Biol Psychiatry 2013 42 135 145
44. Melatonin attenuates antipsychotic metabolic effects: an eightweek randomized, doubleblind, parallelgroup, placebocontrolled clinical trial. RomoNava F, AlvarezIcaza González D, FresánOrellana A, Saracco Alvarez R, BecerraPalars C, Moreno J, Ontiveros Uribe MP, Berlanga C, Heinze G, Buijs RM, Bipolar Disord 2014 16 4 410 421
45. Oxidative injury and potential use of antioxidants in schizophrenia. Mahadik SP, Scheffer RE, Prostaglandins Leukot Essent Fat Acids 1996 55 1-2 45 54
46. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Dakhale G, Khanzode S, Khanzode S, Saoji A, Psychopharmacology 2005 182 4 494 498
47. Vitamin E treatment of tardive dyskinesia. Adler LA, Peselow E, Rotrosen J, Duncan E, Lee M, Rosenthal M, Angrist B, Am J Psychiatry 1993 150 9 1405 1407
48. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. Lohr JB, Caligiuri MP, J Clin Psychiatry 1996 57 4 167 173
49. Vitamin E in the treatment of tardive dyskinesia: the possible involvement of free radical mechanisms. Lohr JB, Cadet JL, Lohr MA, Larson L, Wasli E, Wade L, Hylton R, Vidoni C, Jeste DV, Wyatt RJ, Schizophr Bull 1988 14 2 291
50. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Elkashef AM, Wyatt RJ, Schizophr Bull 1999 25 4 731 740
51. Vitamin E for neuroleptic-induced tardive dyskinesia. Soares-Weiser K, Maayan N, McGrath J, Cochrane Database Syst Rev 2011 2 doi:10.1002/14651858.CD000209.pub2
52. Dietary essential fatty acids and brain function: a developmental perspective on mechanisms. Wainwright PE, Proc Nutr Soc 2002 61 01 61 69
53. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. McNamara RK, Carlson SE, Prostaglandins Leukot Essent Fat Acids 2006 75 4 329 349
54. The membrane hypothesis of schizophrenia. Horrobin DF, Glen AIM, Vaddadi K, Schizophr Res 1994 13 3 195 207
55. Arachidonic acid: a common link in the biology of schizophrenia? Peet M, Laugharne J, Horrobin D, Reynolds G, Arch Gen Psychiatry 1994 51 8 665
56. Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G, J Psychiatr Res 1995 29 3 227 232
57. Fatty acid levels in the brains of schizophrenics and normal controls. Horrobin DF, Manku MS, Hillman H, Iain A, Glen M, Biol Psychiatry 1991 30 8 795 805
58. Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients. Yao JK, Leonard S, Reddy RD, Schizophr Res 2000 42 1 7 17
59. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Assies J, Lieverse R, Vreken P, Wanders RJ, Dingemans PM, Linszen DH, Biol Psychiatry 2001 49 6 510 522
60. Polyunsaturated fatty acids and their metabolites in the pathobiology of schizophrenia. Das UN, Prog Neuro-Psychopharmacol Biol Psychiatry 2013 42 122 134
61. Long-chain {omega}-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE, Arch Gen Psychiatry 2010 67 2 146
62. Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP, Schizophr Res 2003 62 3 195 204
63. A review of the possible role of the essential fatty acids and fish oils in the aetiology, prevention or pharmacotherapy of schizophrenia. Akter K, Gallo DA, Martin SA, Myronyuk N, Roberts RT, Stercula K, Raffa RB, J Clin Pharm Ther 2012 37 2 132 139
64. Influence of green tea and its three major components upon low-density lipoprotein oxidation. Yokozawa T, Dong E, Exp Toxicol Pathol 1997 49 5 329 335
65. Theanine, a specific glutamate derivative in green tea, reduces the adverse reactions of doxorubicin by changing the glutathione level. Sugiyama T, Sadzuka Y, Cancer Lett 2004 212 2 177 184
66. L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study. Ritsner MS, Miodownik C, Ratner Y, Shleifer T, Mar M, Pintov L, Lerner V, J Clin Psychiatry 2011 72 1 34
67. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to l-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients. Miodownik C, Maayan R, Ratner Y, Lerner V, Pintov L, Mar M, Weizman A, Ritsner MS, Clin Neuropharmacol 2011 34 4 155 160
68. Schizophrenia: a new approach. Osmond H, Smythies J, Br J Psychiatry 1952 98 411 309 315
69. Smythies JR, Alarcon RD, Bancroft AJ, Monti JA, Morere DA, Tolbert LC, Walter-Ryan WG, Role of the one-Carbon Cycle in Neuropsychiatry. Biological Methylation and Drug Design New York: Springer 1986 351 362
70. One-carbon metabolism and schizophrenia: current challenges and future directions. Krebs M, Bellon A, Mainguy G, Jay T, Frieling H, Trends Mol Med 2009 15 12 562 570
71. Folic acid, homocysteine and one-carbon metabolism: a review of the essential biochemistry. Scott JM, Weir DG, J Cardiovasc Risk 1998 5 4 223 227 Epub 1999/01/27
72. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Muntjewerff J-W, Kahn RS, Blom HJ, den Heijer M, Mol Psychiatry 2006 11 2 143 149
73. The role of one-carbon metabolism in schizophrenia and depression. Frankenburg FR, Harv Rev Psychiatry 2007 15 4 146 160
74. Schizophrenia and single-carbon metabolism. Regland B, Prog Neuro-Psychopharmacol Biol Psychiatry 2005 29 7 1124 1132
75. One-carbon metabolism in psychiatric illness. Sugden C, Nutr Res Rev 2006 19 01 117 136
76. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Mattson MP, Shea TB, Trends Neurosci 2004 26 3 137 146
77. Folate, homocysteine, and negative symptoms in schizophrenia. Goff DC, Bottiglieri T, Arning E, Shih V, Freudenreich O, Evins AE, Henderson DC, Baer L, Coyle J, Am J Psychiatr 2004 161 9 1705 1708
78. Homocysteine metabolism and B-vitamins in schizophrenic patients: low plasma folate as a possible independent risk factor for schizophrenia. Muntjewerff J-W, van der Put N, Eskes T, Ellenbroek B, Steegers E, Blom H, Zitman F, Psychiatry Res 2003 121 1 1 9
79. Vitamin B12 and folate serum levels in newly admitted psychiatric patients. Lerner V, Kanevsky M, Dwolatzky T, Rouach T, Kamin R, Miodownik C, Clin Nutr 2006 25 1 60 67
80. Genetic variation throughout the folate metabolic pathway influences negative symptom severity in schizophrenia. Roffman JL, Brohawn DG, Nitenson AZ, Macklin EA, Smoller JW, Goff DC, Schizophr Bull 2013 39 2 330 338
81. Enhancement of recovery from psychiatric illness by methylfolate. Godfrey PSA, Toone BK, Bottiglien T, Laundy M, Reynolds EH, Carney MWP, Flynn TG, Chanarin I, Lancet 1990 336 8712 392 395
82. Randomized multicenter investigation of folate plus vitamin b12 supplementation in schizophrenia. Roffman JL, Lamberti J, Achtyes E, Macklin EA, Galendez GC, Raeke LH, Silverstein NJ, Smoller JW, Hill M, Goff DC, JAMA Psychiatry 2013 70 5 481 489
83. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Gilbody S, Lewis S, Lightfoot T, Am J Epidemiol 2007 165 1 1 13
84. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Levine J, Stahl Z, Sela B-A, Ruderman V, Shumaico O, Babushkin I, Osher Y, Bersudsky Y, Belmaker RH, Biol Psychiatry 2006 60 3 265 269
85. Identification of tissue transglutaminase as the autoantigen of celiac disease. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, Schuppan D, Nat Med 1997 3 7 797 801
86. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Fasano A, Catassi C, Gastroenterology 2001 120 3 636 651
87. Gluten-free diet and quality of life in patients with screen-detected celiac disease. Mustalahti K, Lohiniemi S, Collin P, Vuolteenaho N, Laippala P, Maki M, Eff Clin Pract 2002 5 3 105 113
88. Childhood schizophrenia. Bender L, Psychiatry Q 1953 27 1 663 681
89. Celiac syndrome in the case histories of five schizophrenics. Graff H, Handford A, Psychiatry Q 1961 35 2 306 313
90. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Eaton WW, Byrne M, Ewald H, Mors O, Chen C-Y, Agerbo E, Mortensen PB, Am J Psychiatr 2006 163 3 521 528
91. The gluten connection: the association between schizophrenia and celiac disease. Kalaydjian A, Eaton W, Cascella N, Fasano A, Acta Psychiatr Scand 2006 113 2 82 90
92. Novel immune response to gluten in individuals with schizophrenia. Samaroo D, Dickerson F, Kasarda DD, Green PHR, Briani C, Yolken RH, Alaedini A, Schizophr Res 2010 118 1 248 255
93. Neurologic and psychiatric manifestations of celiac disease and gluten sensitivity. Jackson JR, Eaton WW, Cascella NG, Fasano A, Kelly DL, Psychiatry Q 2012 83 1 91 102
94. Relapsed schizophrenics: more rapid improvement on a milk-and cereal-free diet. Dohan FC, Grasberger J, Lowell F, Johnston H, Arbegast AW, Br J Psychiatry 1969 115 522 595 596
95. Relapsed schizophrenics: earlier discharge from the hospital after cereal-free, milk-free diet. Dohan F, Grasberger J, Am J Psychiatry 1973 130 6 685 688
96. Wheat gluten as a pathogenic factor in schizophrenia. Singh MM, Science 1976 191 4225 401 402
97. A double-blind gluten-free/gluten-load controlled trial in a secure ward population. Vlissides DN, Venulet A, Jenner F, Br J Psychiatry 1986 148 4 447 452
98. Wheat gluten challenge in schizophrenic patients. Potkin SG, Weinberger D, Kleinman J, Nasrallah H, Luchins D, Bigelow L, Linnoila M, Fischer SH, Bjornsson TD, Carman J, Gillin JC, Wyatt RJ, Am J Psychiatry 1981 138 1208 11
99. Effects of gluten on schizophrenics. Storms LH, Clopton JM, Wright C, Arch Gen Psychiatry 1982 39 3 323 327
100. Lack of effect of a gluten-free diet on neuroleptic blood levels in schizophrenic patients. Osborne M, Crayton JW, Javaid J, Davis JM, Biol Psychiatry 1982 17 5 627 629
101. Another look at gluten in schizophrenia. Rice JR, Ham CH, Gore WE, Am J Psychiatry 1978 135 11 1417 1418
102. Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia? McGrath J, Schizophr Res 1999 40 3 173 177
103. Vitamin d3 and brain development. Eyles D, Brown J, Mackay-Sim A, McGrath J, Feron F, Neuroscience 2003 118 3 641 653
104. Season of birth in schizophrenia: a review of evidence, methodology, and etiology. Bradbury TN, Miller GA, Psychol Bull 1985 98 3 569
105. Urban birth and residence as risk factors for psychoses: an analysis of 1880 data. Torrey EF, Bowler AE, Clark K, Schizophr Res 1997 25 3 169 176
106. Schizophrenia and migration: a meta-analysis and review. Cantor-Graae E, Selten J-P, Am J Psychiatr 2005 162 1 12 24
107. Prenatal malnutrition and adult schizophrenia: further evidence from the 1959-1961 Chinese famine. Xu M-Q, Sun W-S, Liu B-X, Feng G-Y, Yu L, Yang L, He G, Sham P, Susser E, St Clair D, He L, Schizophr Bull 2009 35 3 568 576
108. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Eyles DW, Burne TH, McGrath JJ, Front Neuroendocrinol 2013 34 1 47 64
109. Developmental vitamin D deficiency and risk of schizophrenia: a 10-year update. McGrath JJ, Burne TH, Féron F, Mackay-Sim A, Eyles DW, Schizophr Bull 2010 36 6 1073 1078
110. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. McGrath J, Saari K, Hakko H, Jokelainen J, Jones P, Järvelin M-R, Chant D, Isohanni M, Schizophr Res 2004 67 2 237 245
111. Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33 000 women from the general population. Hedelin M, Löf M, Olsson M, Lewander T, Nilsson B, Hultman CM, Weiderpass E, BMC Psychiatry 2010 10 1 38
112. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? McCann JC, Ames BN, FASEB J 2008 22 4 982 1001